For patients grappling with immuno-inflammatory diseases and few treatment options, Aclaris Therapeutics, Inc. is working to change the landscape. The clinical-stage biopharmaceutical company has now secured $21.0M in Series b funding to advance its pipeline of novel drug candidates.
Aclaris's multi-stage portfolio is powered by a robust R&D engine, which explores protein kinase regulation to develop new therapies. This capital infusion will support the continued development of these candidates, aiming to address significant unmet medical needs.















